Interne link ProQR Announces First Quarter 2020 Operating and Financial Results mei 07, 2020 om 11:00 AM UTC
Interne link ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update maart 31, 2020 om 10:00 AM UTC
Interne link ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome maart 25, 2020 om 08:15 PM UTC
Interne link ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update februari 26, 2020 om 12:00 PM UTC
Interne link ProQR to Present at Cowen and Company 40th Annual Health Care Conference februari 24, 2020 om 12:00 PM UTC
Interne link ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases februari 06, 2020 om 12:00 PM UTC
Interne link ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a januari 30, 2020 om 12:00 PM UTC
Interne link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa december 11, 2019 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa november 21, 2019 om 12:00 PM UTC
Interne link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 november 06, 2019 om 12:00 PM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares oktober 18, 2019 om 12:20 PM UTC
Interne link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares oktober 16, 2019 om 03:17 AM UTC
Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares oktober 15, 2019 om 09:15 PM UTC
Interne link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 oktober 15, 2019 om 08:08 PM UTC
Interne link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10 oktober 11, 2019 om 10:02 AM UTC
Interne link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients oktober 10, 2019 om 10:00 AM UTC
Interne link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO oktober 07, 2019 om 11:00 AM UTC
Interne link ProQR to Present at Two Investor Conferences in October september 30, 2019 om 11:00 AM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa september 09, 2019 om 11:00 AM UTC
Interne link ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) augustus 12, 2019 om 11:00 AM UTC
Interne link ProQR Announces Financial Results for the Second Quarter of 2019 augustus 07, 2019 om 11:00 AM UTC
Interne link L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 juli 29, 2019 om 04:37 PM UTC